KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$30.9 million.

  • Xenon Pharmaceuticals' Net Cash Flow rose 3723.23% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 24967.48%. This contributed to the annual value of -$4.3 million for FY2024, which is 10467.89% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Net Cash Flow stood at -$30.9 million, which was up 3723.23% from $18.1 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Net Cash Flow peaked at $254.3 million during Q2 2022, and registered a low of -$263.8 million during Q3 2022.
  • For the 5-year period, Xenon Pharmaceuticals' Net Cash Flow averaged around $1.8 million, with its median value being $5.3 million (2021).
  • The largest annual percentage gain for Xenon Pharmaceuticals' Net Cash Flow in the last 5 years was 542758.69% (2022), contrasted with its biggest fall of 505306.05% (2022).
  • Xenon Pharmaceuticals' Net Cash Flow (Quarter) stood at $87.8 million in 2021, then tumbled by 153.59% to -$47.1 million in 2022, then skyrocketed by 203.74% to $48.8 million in 2023, then grew by 15.21% to $56.2 million in 2024, then tumbled by 154.87% to -$30.9 million in 2025.
  • Its last three reported values are -$30.9 million in Q3 2025, $18.1 million for Q2 2025, and -$26.0 million during Q1 2025.